Please login to the form below

Not currently logged in
Email:
Password:

Dr Michael Mehler joins leon-nanodrugs as CEO

He succeeds Dr Ted Odlaug

leon-nanodrugs Michael MehlerMunich-headquartered leon-nanodrugs has appointed Dr Michael Mehler as chief executive officer, succeeding Dr Ted Odlaug who moves to the supervisory board.

Dr Mehler brings over 25 years of leadership experience in the pharma and biotech industries, most recently as chief executive of SpePharm, a Switz specialty hospital products developer.

Prior to this, he was chief executive officer of Riemser Pharma, and held a number of positions at Actelion Pharmaceuticals, Merck & Co and Novartis.

Dr Hubert Birner, chairman of the leon-nanodrugs board, said: “We welcome Michael to lead leon nanodrugs on our joint journey to continued growth and internationalisation.

“We know Michael as a very experienced executive and look forward to working with him.

“We would also like to express our sincere appreciation to Ted who did a tremendously impressing job - he will obviously bring his valuable expertise to the board in his new role and continue to complement our management team.”

18th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics